Trial Profile
A Phase 2 Randomized, Multicenter, Double-blind, Vehicle Controlled, 90-Day, Safety, Efficacy & Systemic Exposure Study of Trifarotene (CD5789) Cream HE1 in Adults and Adolescents With Autosomal Recessive Ichthyosis With Lamellar Scale
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2023
Price :
$35
*
At a glance
- Drugs Trifarotene (Primary)
- Indications Ichthyosis
- Focus Therapeutic Use
- Sponsors Mayne Pharma
- 13 Sep 2021 Status changed from recruiting to discontinued.
- 15 Aug 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 02 Mar 2021 Planned End Date changed from 4 Dec 2020 to 4 Mar 2022.